Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11641791 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Okutani Y, et al. (2001) Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 20, 6643-50 11641791
Download Sites

Y694-p - STAT5A (human)
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody
 Relevant cell lines - cell types - tissues:  F-36P (erythroid), K562 (erythroid)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Src (human) pharmacological inhibitor of upstream enzyme, transfection of dominant-negative enzyme, transfection of wild-type enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Epo increase
PP3 Epo no effect upon treatment-induced increase
PP1 Epo inhibit treatment-induced increase
PP2 Epo inhibit treatment-induced increase
AG490 Epo inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.